Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Clinical trial NCT07037433 · RECRUITING
Trial details
- NCT number
- NCT07037433
- Sponsor
- Amgen
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-25
- Primary completion
- 2028-06-30
- Enrollment
- 12800
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.